Q1 2024 BioCardia Inc Earnings Call Transcript
Key Points
- BioCardia Inc reported positive results from three ongoing autologous and allogeneic cell therapy clinical trials, showing reduced mortality and major adverse cardiac events.
- The company highlighted an 86% relative risk reduction in heart death equivalents and a 24% relative risk reduction in non-fatal major adverse cardiac and cerebral vascular events in certain patients.
- BioCardia Inc is on track to submit final results for regulatory submission in Japan by the fourth quarter of 2024, with high expectations based on preliminary data.
- Medicare reimbursement approval for the confirmatory cardiac heart failure trial is expected to reduce study costs by more than $5 million, enhancing financial efficiency.
- The company has established multiple biotherapeutic clinical programs and partnerships, aiming to provide significant shareholder returns and achieve commercial approvals as early as 2025.
- Revenue for Q1 2024 was relatively low at $55,000, showing a slight decrease from $65,000 in the same period the previous year.
- The company continues to operate at a net loss, reporting a $2.3 million loss for Q1 2024, although this is an improvement from a $3.5 million loss in Q1 2023.
- BioCardia Inc is still in the process of completing trials and regulatory submissions, with critical data yet to be finalized and submitted.
- There are inherent risks involved with the development of new product technologies and obtaining regulatory approvals, which could impact future performance.
- The company's dependency on the success of clinical trials and regulatory approvals for future revenue and growth presents significant operational and financial risks.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Biocartis First Quarter 2024 financial results and business update conference call. At this time, all participants are in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions to ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call.
I would now like to turn the call over to Maureen, though, Miranda Peyto of bio Cardia, Investor Relations. Please go ahead, Miranda.
Thanks, Debbie. Good afternoon, and thank you for participating in today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
